The T(PEAK) of propofol measured by the A-line auditory-evoked potential monitor is different from that measured by the Aspect A-2000 bispectral index monitor. The T(PEAK)s of propofol from auditory-evoked potential index and bispectral index, and the values of k(e0) calculated based on T(PEAK)s are different from previous reports and appear to be not affected by age. Further studies need to be taken to validate clinically the k(e0) values of propofol.

The pharmacokinetics of dexmedetomidine were best described by a two-compartment model in our study. The pharmacokinetic parameters of dexmedetomidine in patients with end-stage renal failure and hyperparathyroidism were similar to those in patients with normal renal function. Further studies of dexmedetomidine pharmacokinetics are recommended to optimize its clinical use.